FAPI-74 PET/CT

Phase 3Small molecule

SSOFIE

FAPI-74 PET/CT is one of 114 small molecule programs targeting Esophageal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

113

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal CancerActive, not recruiting

Intestinal CancerActive, not recruiting

Pancreatic Ductal AdenocarcinomaActive, not recruiting

Esophageal CancerPhase 3

Active, not recruiting

Intestinal CancerPhase 2

Active, not recruiting

Pancreatic Ductal AdenocarcinomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

341 competitors in Esophageal Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

48 2

Eloxatin

Teva

Phase 3

34 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

57 4

Paraplatin

AAvyxa

Phase 3

30 5

Adrucil

EElorac, Inc.

Phase 3

27 6

Camptosar

Pfizer

Phase 3

10 7

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

19 8

Erbitux

IImclone

Phase 3

16 9

Ellence

Merck & Co.

Phase 3

2 10

Stivarga

Bayer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Recruiting

Esophageal Cancer

NCT07217704

Q4 2027

Phase 3Recruiting

Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07217717

Clinical

Trials by Indication[1]

Intestinal Cancer1 trial

Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers

Completed·SSOFIE·Phase 2·NCT05641896·109 enrolled

Esophageal Cancer1 trial

A Phase 3, Multicenter, Prospective Open-Label Study of the Diagnostic Performance of [¹⁸F]FAPI-74 PET/CT for the Detection of Metastatic Disease in Adults With Gastric or Esophageal Cancer

Recruiting·SSOFIE·Phase 3·NCT07217704·200 enrolled

Pancreatic Ductal Adenocarcinoma (PDAC)1 trial

A Phase 3, Multicenter, Prospective Open-Label Study of the Diagnostic Performance of [¹⁸F]FAPI-74 PET/CT for the Detection of Metastatic Disease in Adults With Pancreatic Ductal Adenocarcinoma

Recruiting·SSOFIE·Phase 3·NCT07217717·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for FAPI-74 PET/CT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FAPI-74 PET/CT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FAPI-74 PET/CT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SOFIE company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSOFIE

FAPI-74 PET/CT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Trials by Indication[1]

Intestinal Cancer1 trial

Esophageal Cancer1 trial

Pancreatic Ductal Adenocarcinoma (PDAC)1 trial

References

Drug Info

Quick Facts

Related News